Comparison
BPC-157 vs. DSIP
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Healing
Research other
CAS no.
137525-51-0
62568-57-4
Molecular weight
1419.5 g/mol
848.81 g/mol
Half-life
4 h
0.1 h
Sequence
GEPPPGKPADDAGLVTrp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GluMechanism of action
BPC-157
Synthetic peptide derived from a sequence of a protein found in gastric juice. In preclinical models, an influence on angiogenic and tissue-protective signalling pathways has been described. The precise molecular mechanisms of action are not conclusively understood.
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Evidence base
Highest evidence
Animal model
Human trial
Studies
4
4
of which in humans
0
1
Effects recorded
4
3
Open conflicts
2
1
Documented adverse events
2
1